# US 2010/0143466 A1 · Modified release ibuprofen dosage form

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0143466 A1
- Document ID: US20100143466A1
- Status: Published application
- Kind: A1
- Application number: 12/706,429
- Filed: 2010-02-16
- Published: 2010-06-10
- Earliest claimed: 2004-09-30
- Assignees: SCOLR Pharma, Inc.
- Inventors: Michael Hite; Cathy Federici; Alan Brunelle; Stephen Turner
- Web page: https://patentgrep.com/patent/US20100143466A1

## CPC

- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 47/02: Inorganic compounds
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is a solid dosage form for oral administration of ibuprofen comprising a modified release formulation of ibuprofen which provides an immediate burst effect and thereafter a sustained release of sufficient ibuprofen to maintain blood levels at least 6.4 μg/ml over an extended period of at least 8 hours following administering of a single dose.

## Claims

### Claim 1

A solid dosage form for modified oral administration of ibuprofen comprising:
two or more hydrophilic polymers having two different viscosities, wherein the two different viscosities are at least one order of magnitude apart from one another;
300 to 800 mg of ibuprofen in the solid dosage form uniformly dispersed in said polymer;
a dissolution additive dispersed in said two or more hydrophilic polymers in an amount in the range of 10% to 35% by weight of the ibuprofen, said dissolution additive comprising an alkali metal salt, an amino acid having a neutral to alkaline side chain, croscarmellose or a salt thereof, or a combination of any two of such dissolution additives; and
an inert formulation additive dispersed in said two or more hydrophilic polymers in an amount in the range of 15% to 75% by weight of the ibuprofen, said formulation additive comprising microcrystalline cellulose, silica, magnesium stearate, stearic acid, lactose, pre-gelatinized starch, dicalcium phosphate or a combination of any of them,
wherein said solid dosage form comprises a monolithic, directly compressed tablet and releases at least 20% of the ibuprofen within 2 hours following oral administration or exposure to an agitated aqueous medium of a single dosage unit, then thereafter releases ibuprofen at a relatively constant rate over a period of at least 8 hours, and wherein at least 70% of the ibuprofen is released over a period of not more than 14 hours following such administration or exposure.

### Claim 2 (depends on 1)

The solid dosage form of claim 1, wherein ibuprofen is present in each tablet in an amount of about 300 mg, 400 mg, or 600 mg.

### Claim 3 (depends on 1)

The solid dosage form of claim 1, wherein ibuprofen is present in each tablet in an amount of about 600 mg.

### Claim 4 (depends on 1)

The solid dosage form of claim 1, wherein said two or more hydrophilic polymers comprise polyethylene oxide, hydroxypropyl methylcellulose, or a combination thereof.

### Claim 5 (depends on 1)

The solid dosage form of claim 1, wherein said two or more hydrophilic polymers consist of hydroxypropyl methylcellulose having two different viscosities.

### Claim 6 (depends on 1)

The solid dosage form of claim 1, wherein said two or more hydrophilic polymers comprise hydroxypropyl methylcellulose having two different viscosities, at a concentration of 17% to 42% by weight of ibuprofen.

### Claim 7 (depends on 1)

The solid dosage form of claim 1, wherein said two or more hydrophilic polymers comprise a first hydrophilic polymer comprising hydroxypropyl methylcellulose having a viscosity of about 100 cps and a second hydrophilic polymer comprising hydroxypropyl methylcellulose having a viscosity of between about 4000 cps to about 100,000 cps.

### Claim 8 (depends on 7)

The solid dosage form of claim 7, wherein the viscosity of the second hydrophilic polymer is about 4,000 cps.

### Claim 9 (depends on 7)

The solid dosage form of claim 7, wherein the first hydrophilic polymer is present at a concentration in the range of 5% to 20% by weight of the ibuprofen and the second hydrophilic polymer has a viscosity of about 4000 cps and is present at a concentration in the range of about 10% to about 30% by weight of the ibuprofen.

### Claim 10 (depends on 1)

The solid dosage form of claim 1, wherein said polymer comprises hydroxypropyl methylcellulose having two different viscosities, selected from the group consisting of 100 cps, 4,000 cps, 10,000 cps, 15,000 cps, and 100,000 cps

### Claim 11 (depends on 1)

The solid dosage form of claim 1, wherein the inert formulation additive comprises a first inert formulation additive having a first average particle size and a second inert formulation additive having a second average particle size, wherein the first and second inert formulation additives are each present in an amount in the range of 15% to 35% by weight of the ibuprofen.

### Claim 12 (depends on 11)

The solid dosage form of claim 11, wherein said first inert formulation additive comprises a first microcrystalline cellulose having the first average particle size and said second inert formulation additive comprises a second microcrystalline cellulose having the second average particle size, wherein each such microcrystalline cellulose is present at a concentration in the range of about 15% to about 35% by weight of the ibuprofen, the combination of which comprises from about 40% to about 60% by weight of the ibuprofen.

### Claim 13 (depends on 12)

The solid dosage form of claim 12, wherein the first average particle size is about 60 microns and the second average particle size is about 110 microns.

### Claim 14 (depends on 1)

The solid dosage form of claim 1, wherein said dissolution additive is selected from the group consisting of sodium carbonate, glycine, arginine, and croscarmellose sodium, and a combination thereof.

### Claim 15 (depends on 1)

The solid dosage form of claim 1, wherein the solid dosage form is formed by mixing the two or more hydrophilic polymers, the ibuprofen, the dissolution additive, and the inert formulation additive to form a powder and then compressing the powder to form the tablet, without granulation or roller compaction.

### Claim 16 (depends on 1)

The solid dosage form of claim 1, wherein the inert formulation additive comprises microcrystalline cellulose.

### Claim 17 (depends on 16)

The solid dosage form of claim 16, wherein the inert formulation additive further comprises silica, stearic acid, or both of them.

### Claim 18 (depends on 1)

The solid dosage form of claim 1, wherein:
the two or more hydrophilic polymers comprise hydroxypropyl methylcellulose having two different viscosities;
the inert formulation additive comprises a first microcrystalline cellulose having the first average particle size and a second microcrystalline cellulose having a second average particle size; and
the dissolution additive comprises glycine and croscarmellose sodium.

### Claim 19 (depends on 18)

The solid dosage form of claim 18, wherein the inert formulation further comprises silica and stearic acid.

### Claim 20 (depends on 18)

The solid dosage form of claim 18, wherein the first and second microcrystalline cellulose comprise silicified microcrystalline cellulose.

### Claim 21

A solid dosage form for modified oral administration of ibuprofen comprising:
a first hydrophilic polymer comprising hydroxypropyl methylcellulose having a viscosity of about 100 cps and a second hydrophilic polymer comprising hydroxypropyl methylcellulose having a viscosity of between about 4000 cps to about 100,000 cps;
300 to 800 mg of ibuprofen in the solid dosage form uniformly dispersed in said first hydrophilic polymer and said second hydrophilic polymer;
a dissolution additive dispersed in said first hydrophilic polymer and in said second hydrophilic polymer in an amount in the range of 10% to 35% by weight of the ibuprofen, said dissolution additive comprising glycine and croscarmellose sodium; and
a first inert formulation additive comprising a first microcrystalline cellulose having a first average particle size and a second inert formulation additive comprising a second microcrystalline cellulose having a second average particle size, wherein each such microcrystalline cellulose is present at a concentration in the range of about 15% to about 35% by weight of the ibuprofen, the combination of which comprises from about 40% to about 60% by weight of the ibuprofen, wherein said first formulation additive and said second inert formulation additive are dispersed in said first hydrophilic polymer and said second hydrophilic polymer;
wherein said solid dosage form comprises a monolithic, directly compressed tablet and releases at least 20% of the ibuprofen within 2 hours following oral administration or exposure to an agitated aqueous medium of a single dosage unit, then thereafter releases ibuprofen at a relatively constant rate over a period of at least 8 hours, and wherein at least 70% of the ibuprofen is released over a period of not more than 14 hours following such administration or exposure.

### Claim 22

A method for providing immediate and extended release of ibuprofen to a subject, comprising administering to a subject in a single dosage form comprising a monolithic, directly compressed tablet, said tablet comprising:
two or more hydrophilic polymers having two different viscosities, wherein the two different viscosities are at least one order of magnitude apart from one another;
300 to 800 mg of ibuprofen in the solid dosage form uniformly dispersed in said two or more hydrophilic polymers;
a dissolution additive dispersed in said two or more hydrophilic polymers in an amount in the range of 10% to 35% by weight of the ibuprofen, said dissolution additive comprising an alkali metal salt, an amino acid having a neutral to alkaline side chain, croscarmellose or a salt thereof, or a combination of any two of such dissolution additives; and
an inert formulation additive dispersed in said two or more hydrophilic polymers in an amount in the range of 15% to 75% by weight of the ibuprofen, said formulation additive comprising microcrystalline cellulose, silica, magnesium stearate, stearic acid, lactose, pre-gelatinized starch, dicalcium phosphate or a combination of any of them,
wherein said tablet releases at least 20% of the ibuprofen within 2 hours following oral administration or exposure to an agitated aqueous medium of a single dosage unit, then thereafter releases ibuprofen at a relatively constant rate over a period of at least 8 hours, and wherein at least 70% of the ibuprofen is released over a period of not more than 14 hours following such administration or exposure.
